Emergent Biosol: (NYSE: EBS)

$14.56

0.13 (0.90%)

Volume 206,842

May 17 04:01 PM ET

Zacks Rank: 3-Hold

Zacks Rank	Definition	Annualized Return
#1	Strong Buy	26.6%
#2	Buy	18.71%
#3	Hold	10.12%
#4	Sell	4.32%
#5	Strong Sell	2.16%
S&P	500	9.93%

Overview Quote

            Stock Activity
        
		Day Low - High
		14.26 - 14.65
	
		52wk Low - High
		12.50 - 16.99
	
		Previous Close
		14.43
	
		Avg. Volume
		227,599
	
		Industry
		MED-BIOMED/GENE
	
		Market Cap
		523.08 M
	
		Div - Yield
		0.00 - 0.00
	
		Beta
		-0.05
	
		PE (Forward)
		18.91
	
		Current Year Est.
		0.77
	
		Quarterly Earnings ESP 
		0.00%
	
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

                Premium research
            
		Zacks Rank  Short-Term: 1-3 Months
                                                                
                                                                Zacks #1 Rank Strong Buys
                                                                
                                                            This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below. 

                                                                        Zacks Rank
                                                                        Definition
                                                                        Annualized Return
                                                                    
                                                                        #1
                                                                        Strong Buy
                                                                        26.6%
                                                                    
                                                                        #2
                                                                        Buy
                                                                        18.71%
                                                                    
                                                                        #3
                                                                        Hold
                                                                        10.12%
                                                                    
                                                                        #4
                                                                        Sell
                                                                        4.32%
                                                                    
                                                                        #5
                                                                        Strong Sell
                                                                        2.16%
                                                                    
                                                                        S&P
                                                                        500
                                                                        9.93%
                                                                    
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
                                                        
		3
Hold

		Zacks Recommendation  Long-Term: 6+ Months
                                                                
                                                                All Outperform Rated Stocks
                                                                
                                                            Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.
The Zacks Recommendations are split into 3 groups: Buy, Hold and Sell. Our Buy recommendations have generated returns of 34.4% in 2006, and 16.69% in 2007. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock.    More on these reports below.

                                                                    Difference Between Zacks Rank and Zacks Recommendation

                                                                    Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations
                                                                
		Neutral
	
		Zacks Industry Rank Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.
When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

                                                                About Zacks Industry Rank

                                                                Zacks Industry Rank - All current industry ranks. 

                                                                Zacks Premium - The only way to get access to the Zacks Industry Rank
                                                            
		91 out of 265
	
		Equity Research Report The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

                                        Zacks Equity Research Home
                                        Zacks Premium - The only way to get access to Zacks Recommendations
                                    
Updated as of 05/3/2013

		PREMIUM
	
    (  = Change in last 30 days) 
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial 
Zacks Premium Home | Zacks Rank Stock Education

                Key Earnings Data
            
                            PE (Forward)
                            18.91
                        
                            PEG Ratio
                            1.89
                        
                            Current Year Est.
                            0.77
                        
                            Current Quarter Estimate
                            0.22
                        
                            Most Accurate Estimate
                            0.22
                        
                            Earnings ESP 
                            0.00%
                        
                            Next Earnings Report Date
                            08-08-2013
                        
                            EPS Last Year
                            0.61
                        
                            Expected Earnings Growth
                            10.00%
                        
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

            Company Description
        
EMERGENT BIOSULUTIONS INC. is a leading biopharmaceutical company dedicated to one simple mission - to protect life. EBS develops, manufactures and commercializes vaccines and therapeutics that assist the body's immune system to prevent or treat disease. Their products target infectious diseases and other medical conditions that have resulted in significant unmet or underserved public health needs. Their marketed product, BioThrax? (Anthrax Vaccine Adsorbed), is the only vaccine approved by the U.S. Food and Drug Administration for the prevention of anthrax infection.   
Full EBS Company Report

        
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

            Interactive Java Charting | Fundamental Charts
        
            <a href="#"><img id="dart_image_1" src="http://b7d61a7c6b8c307bf531-a92a66b9587e2a0aa805bd4e70b98407.r95.cf2.rackcdn.com/images/zacks/logos/zacks_logo_230x76.png" width="336" height="280" border="0" alt="" /></a>        
Turn Earnings Surprises into quick profits.
 
EBS Chart  by YCharts

Earnings Estimates

	Current Qtr (06/2013)	Next Qtr (09/2013)	Current Year (12/2013)	Next Year (12/2014)
Average Estimate	0.22	0.26	0.77	0.94
Number of Estimates	3	3	4	4
Low Estimate	0.18	0.23	0.68	0.73
High Estimate	0.26	0.29	0.86	NA
Year Ago EPS	0.21	0.18	0.82	0.77
EPS Growth	4.76%	46.30%	-6.10%	21.43%

More EBS Estimates

Average Earnings Estimates for EBS

EPS Growth for EBS

Industry Analysis

Name	Symbol	Previous Close
EMERGENT BIOSOL	EBS	14.56
AETERNA ZENTARS	AEZS	2.10
ANIKA THERAPEUT	ANIK	14.40
GENTIUM SPA-ADR	GENT	8.87
AASTROM BIOSCI	ASTM	0.57
ACHILLION PHARM	ACHN	7.77
ADDEX THERA LTD	ADDXF	6.94
AFFYMAX INC	AFFY	1.33
ALEXION PHARMA	ALXN	102.90
ALKERMES INC	ALKS	31.69

Sector:Medical>> Industry:MED-BIOMED/GENE

COMPARE TICKER vs. Its Peers

Zacks Commentary

Bearish MACD for Emergent Biosolutions Inc.

Feb 26, 2013

Zacks Rank #5 Addition for Monday

Jan 28, 2013

Emergent Inks Deal with VaxInnate

Dec 31, 2012

Emergent Biosolutions Inc. Enters Oversold Territory

Jul 11, 2012

Report for EBS

May 03, 2013

More EBS Zacks Commentary

Financials

EPS TTM	0.61
Sales	282
Net Income	22
Price/Earnings	23.87
Price/Book	1.20
Price/Cash Flow	12.78
Price/Sales	1.90

More EBS Financials

News

Emergent Biosolutions Earnings Review: 16 Days after Announcement Shares Down 3.6% (EBS) - Financial News Network Online - Earnings Lookback

May 18, 2013

Emergent BioSolutions to Hold Annual Meeting of Stockholders Thursday May 23, 2013 at 9:00 AM Eastern; Webcast Will Be Available - Businesswire

May 16, 2013

Emergent Biosolutions Makes a Move: Down 1.3% - Financial News Network Online - Market Movers

May 15, 2013

CYNO, SPPRP, LINTA, CTCM, EHTH, EBS Are Seasonally Ripe To Go Down In the Next Five Weeks - M2

May 13, 2013

Emergent announces encouraging preclinical data from prostate cancer study - Datamonitor

May 13, 2013

Emergent BioSolutions to Webcast Presentation at Bank of America Merrill Lynch 2013 Health Care Conference - Businesswire

May 9, 2013

Emergent BioSolutions Unveils Preclinical Efficacy Data on ES414 - Close-Up Media

May 8, 2013

Emergent BioSolutions Reports Financial Results for First Quarter 2013 - Close-Up Media

May 7, 2013

See All News Stories on EBS

Broker Recommendations

Current ABR	1.00
ABR (Last Week)	1.00
# of recs in ABR	5
Average Target Price	21.50
Industry Rank by ABR	91 out of 265
Rank in Industry	36 out of 155

More EBS Broker Recommendations

Username: Password:

Remember me [?]

Forgot Password

New Member